Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a ...

This was the ADR's second consecutive day of losses.

FDA grants accelerated approval to AstraZeneca's Datroway for EGFR-mutant NSCLC after prior therapies, with a 45% response ...

AstraZeneca targets $80bn revenue by 2030, driven by oncology and new drugs, but faces patent risks and tough competition. Find out why AZN stock is a hold.

AstraZeneca (NASDAQ:AZN) is one of the most active stocks to buy according to analysts. On June 16, the preliminary results ...

Tempus AI TEM and Guardant Health GH are two dominant players in the field of AI-powered precision oncology. Tempus, newly ...

AstraZeneca PLC closed 22.38% below its 52-week high of £133.88, which the company achieved on September 3rd.

Investing.com -- AstraZeneca (NASDAQ: AZN) on Monday night received accelerated approval from the U.S. Food and Drug ...